MARÍA DOLORES
CABALLERO BARRIGÓN
Investigadora en el periodo 1998-2022
Jagiellonian University
Cracovia, PoloniaPublicaciones en colaboración con investigadores/as de Jagiellonian University (8)
2019
-
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
The Lancet Haematology, Vol. 6, Núm. 2, pp. e67-e78
2018
-
Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: Results from the open-label, multicenter, phase II DAWN study
Journal of Clinical Oncology, Vol. 36, Núm. 23, pp. 2405-2412
-
Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
Leukemia, Vol. 32, Núm. 8, pp. 1799-1803
2017
-
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus
Leukemia and Lymphoma, Vol. 58, Núm. 12, pp. 2824-2832
-
Is good clinical practice becoming poor clinical care?
HemaSphere
2016
-
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study
The Lancet, Vol. 387, Núm. 10020, pp. 770-778
2003
2002
-
Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia
Blood, Vol. 100, Núm. 12, pp. 3877-3886